Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Cash from Financing Activities of $605000.0 for Q2 2026, up 67.59% year-over-year from $361000.0 in Q2 2025, and down 96.96% on a QoQ basis from $19.9 million in Q1 2026.
Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $605000.0 in Q2 2026.
- Cash from Financing Activities for Q2 2026 came in at $605000.0, up 67.59% year-over-year; the trailing twelve-month figure through Jun 2026 was $45.9 million (up 6982.25% YoY), and the FY2025 annual result was $25.7 million, up 4917.15% from the prior year.
- Cash from Financing Activities eased to $605000.0 in Q2 2026, from $19.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $25.3 million in Q4 2025 and troughed at -$202000.0 in Q2 2022.
- A 5-year average of $3.0 million and a median of $153500.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest annual swing landed in 2022, when Cash from Financing Activities plunged 4140.0%; it then surged 86569.57% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $130000.0 in 2022, then soared by 285.38% to $501000.0 in 2023, then plunged by 47.5% to $263000.0 in 2024, then soared by 9526.24% to $25.3 million in 2025, then plunged by 97.61% to $605000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $605000.0 in Q2 2026, $19.9 million in Q1 2026, and $25.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 605,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 605,000.00 |
| Jun 30, 2026 | 605,000.00 |
| Mar 31, 2026 | 19.93 Mn |
| Mar 31, 2026 | 19.93 Mn |
| Dec 31, 2025 | 25.32 Mn |
| Dec 31, 2025 | 25.32 Mn |
| Sep 30, 2025 | 37,000.00 |
| Sep 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 361,000.00 |
| Jun 30, 2025 | 361,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |